Ticagrelor Tablet
Product Images NDC 69452-508

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 69452-508). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bionpharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

60mg-500ct (60mg 500ct)

60mg-500ct (60mg 500ct)
This text provides information about a medication called ticagrelor, with each tablet containing 60 mg of the active ingredient. It includes details on the usual adult dosage, storage conditions (25°C with excursions permitted to 15-30°C), manufacturer (Changzhou Pharmaceutical Factory in China), distributor (Bionpharma Inc. in Princeton, NJ), and packaging information. The text also emphasizes keeping the medication out of the reach of children and mentions the distribution of a Medication Guide to each patient. Please consult the package insert for more detailed dosage instructions.*
FDA Label Image

60mg-60ct (60mg 60ct)

60mg-60ct (60mg 60ct)
Each tablet contains 60 mg ticagrelor. The usual adult dosage and other important information can be found in the package insert. Keep medication out of reach of children. Store at 25°C (77°F), with excursions permitted to 15-30°C (59-86°F). Manufactured by Changzhou Pharmaceutical Factory, Changzhou, Jiangsu, China and distributed by Bionpharma Inc., Princeton, NJ 08540. Revised: 07/2025. Dispense the accompanying Medication Guide to each patient. This product is available in a package of 60 tablets. Monitor the NDC number 69452-508-17 for identification purposes.*
FDA Label Image

90mg-500ct (90mg 500ct)

90mg-500ct (90mg 500ct)
Each tablet contains 90 mg of ticagrelor and should be kept out of reach of children. The usual adult dosage information is available in the package insert. Store at 25°C with excursions permitted to 15-30°C. Manufactured by Changzhou Pharmaceutical Factory in China and distributed by Bionpharma Inc. in Princeton, NJ. It is recommended to dispense the accompanying Medication Guide to each patient. Revision date is 07/2025. The National Drug Code (NDC) is 69452-509-30. This is a prescription medication.*
FDA Label Image

90mg-60ct (90mg 60ct)

90mg-60ct (90mg 60ct)
This is a description of a medication called Ticagrelor in tablet form. Each tablet contains 90 mg of Ticagrelor. The usual adult dosage should be consulted on the package insert. The medication should be kept out of reach of children and stored at 25°C, with excursions permitted to 15-30°C. It is manufactured by Changzhou Pharmaceutical Factory in China and distributed by Bionpharma Inc. in Princeton, NJ. The medication guide should be given to each patient. This information was revised in July 2025.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
FDA Label Image

Figure-01 (Figure 01)

Figure-01 (Figure 01)
This data presents the cumulative percentages of patients using Ticagrelor and Clopidogrel over the course of the study. It shows the percentage of patients with events at different timepoints, as well as the Kaplan-Meier percentage at 12 months. The number of patients for each treatment and the risk values over various days are also provided. This information can be used to assess the efficacy and safety profile of these medications.*
FDA Label Image

Figure-02 (Figure 02)

Figure-02 (Figure 02)
FDA Label Image

Figure-03 (Figure 03)

Figure-03 (Figure 03)
This text seems to show data related to a clinical trial comparing Ticagrelor and Placebo for certain events. The table displays the cumulative percentage over time (in months) for the two groups, and the number of participants at risk at various time points. This information is valuable for analyzing the effectiveness and safety of Ticagrelor compared to Placebo in preventing the specified events.*
FDA Label Image

Figure-04 (Figure 04)

Figure-04 (Figure 04)
This text appears to contain information related to a study comparing Ticagrelor 90 mgbd and Placebo in terms of cumulative event percentages and the number of events and participants involved in the study. It also includes the number of risk days from randomization for both groups.*
FDA Label Image

Figure-05 (Figure 05)

Figure-05 (Figure 05)
The text provides data related to an unknown quantity (possibly measurements or values) along with a scale or identifier for each data point. It also includes time in hours as a variable. This information seems to be part of a data set or a graph, but the context and specific details are not clear.*
FDA Label Image

Figure-06 (Figure 06)

Figure-06 (Figure 06)
FDA Label Image

Figure-07 (Figure 07)

Figure-07 (Figure 07)
FDA Label Image

Figure-08 (Figure 08)

Figure-08 (Figure 08)
This text provides information on the drug Ticagrelor and its interactions with various other drugs. It lists examples of strong CYP3A4 inhibitors, moderate CYP3A4 inhibitors, potent CYP3A4 inducers, P-gP, and CYP3A inhibitors. It also gives recommendations on dose adjustments and concomitant use of these drugs with Ticagrelor. The text includes dosages for certain medications and specifies when to avoid concomitant use. It also mentions a reference section for further details on adjustments and interactions.*
FDA Label Image

Figure-09 (Figure 09)

Figure-09 (Figure 09)
This text includes a table with information about the interaction of Ticagrelor with different drugs. It provides recommendations, dose adjustments, mean effects, and relative changes when combined with Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine. It also mentions the need for monitoring digoxin levels when initiating or changing ticagrelor therapy. The text does not specify the language.*
FDA Label Image

Figure-10 (Figure 10)

Figure-10 (Figure 10)
FDA Label Image

Figure-11 (Figure 11)

Figure-11 (Figure 11)
The extracted text provides statistical data related to a medical study or clinical trial. It includes characteristics of the participants, treatment effects, primary endpoints, and various demographic factors such as geographic distribution, age groups, sex, race, previous medical history, and treatment approaches. The information seems complex and requires further analysis to draw meaningful conclusions or insights.*
FDA Label Image

Figure-12 (Figure 12)

Figure-12 (Figure 12)
FDA Label Image

Figure-13 (Figure 13)

Figure-13 (Figure 13)
FDA Label Image

Figure-14 (Figure 14)

Figure-14 (Figure 14)
FDA Label Image

Figure-15 (Figure 15)

Figure-15 (Figure 15)
FDA Label Image

Figure-16 (Figure 16)

Figure-16 (Figure 16)
This is a statistical analysis of a study comparing the effectiveness of Ticagrelor versus placebo in different subgroups based on characteristics such as age, sex, race, body mass index, geographic region, aspirin dose, medical history, and other factors. The data includes hazard ratios with 95% confidence intervals for various variables, showing the impact of Ticagrelor on different patient groups. It provides insights into how Ticagrelor may be more beneficial compared to placebo in certain populations.*
FDA Label Image

Figure-17 (Figure 17)

Figure-17 (Figure 17)
This text shows the results of a clinical trial comparing the effectiveness of Ticagrelor 90 mg with a placebo in reducing specific events. The trial involved a total of 5523 participants receiving Ticagrelor and 5493 participants receiving Placebo. The events occurred in 303 participants (5.4%) in the Ticagrelor group and 362 participants (6.5%) in the Placebo group. The data also includes a chart showing the number of participants at risk over time from randomization.*
FDA Label Image

Figure-18 (Figure 18)

Figure-18 (Figure 18)
This text appears to contain statistical data related to a medical study or clinical trial. It includes information about patients' demographics (age, sex, race), health characteristics (diagnoses, prior medical history, medication use), and outcomes related to the treatment with Ticagrelor and Placebo. The percentages indicate the distribution of patients within various categories. The data also includes Hazard Ratios (HR) and their 95% Confidence Intervals (CI) for comparing the effectiveness of Ticagrelor and Placebo. This information could be used to assess the efficacy and safety of these treatments in the specified patient population.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.